Citations

Mayo Clinic

Showing 10 of 108537 citations.

Abstract 5078: Sustained Acting Atrial Natriuretic Peptide: A Novel Natriuretic Peptide With Potent Blood Pressure Lowering and Renal Enhancing Properties in a Canine Model of Acute Angiotensin Induced Hypertension
Boerrigter, Guido, Chen, Horng, Martin, F. Elizabeth , McKie, Paul M. , Cataliotti, Alessandro , Burnett, John

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1045 Get It

Background Sustained Acting Atrial Natriuretic Peptide (SA-ANP) is a 40 AA peptide consisting of native ANP (1–28) with a 12 AA C-terminus extension which we synthesized based upon a familial ANP gene frameshift mutation. SA-ANP possesses markedly greater and more sustained mean arterial pressure (MAP) lowering, diuretic/natriuretic, angiotensin-aldosterone suppressing, and cGMP activating properties compared to ANP in normal dogs consistent with a super agonist of the ANP receptor (NPR-A) ( JACC in press ). Here we evaluated SA-ANP in a model of acute hypertension with the hypothesis that SA-ANP would have potent MAP lowering and renal enhancing properties. Methods Integrated physiological studies were performed in a canine model of ANG induced hypertension (20 ng/kg/min continuous infusion) before, during, and up to 3 hours following a 45 minute infusion of SA-ANP (30 pmol/kg/min) (n=6) or vehicle (n=6). Results MAP is shown in Figure 1 . SVR significantly decreased and despite a significant reduction in MAP both renal blood flow (RBF) and GFR were significantly increased following SA-ANP infusion. There were significant reductions in proximal and distal tubule sodium reabsorption resulting in a significant increase (>50 fold) in diuresis and natriuresis with SA-ANP. These renal actions were associated with significant increases in plasma and urine cGMP and a significant inhibition of aldosterone activation. Discussion We report for the first time in an acute model of hypertension that SA-ANP reduced MAP while enhancing RBF, GFR, and sodium/water excretion and thus may serve as a potential therapeutic agent in the treatment of hypertension in the setting of volume overload.
Abstract 4937: A Novel Molecular Imaging Sensor of Cellular Oxidative Stress
Chen, Ian Y. , Simari, Robert D., Gambhir, Sanjiv S. , Rodriguez‐Porcel, Martin , Peterson, Karen M. , Lerman, Amir

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1025-a Get It

Increased oxidative stress has been suggested to play an important role in the biology of mesenchymal stem cells (MSCs). However, little is known of the effect of increased oxidative stress in-vivo, partly due to the lack of appropriate imaging technologies for monitoring of stem cell biology in the living subject. Recent developments in molecular imaging permit, for the first time, the longitudinal monitoring of stem cell biology in vivo. We hypothesize that changes in oxidative stress can be monitored using a reporter gene strategy (molecular imaging). Methods: We have developed a novel oxidative stress sensor, using a two-step transcriptional amplification strategy to enhance the expression of firefly luciferase (Fluc), driven by the pro-oxidant enzyme NAD(P)H promoter, and used to monitor oxidative stress in rMSCs. rMSCs was induced by hypoxia (1% O2 for 24 hours) and serum deprivation (SD) and confirmed using a dichlorofluorescein colorimetric assay (measures the production of hydrogen peroxide-H2O2-) and NAD(P)H protein expression. Results: Both serum deprivation and hypoxia led to a pro-oxidant state (Fig. A–B ). Most importantly, increased oxidative stress led to increased activity of the novel reporter gene sensor (Fig. C ) which was decreased in the presence of antioxidants (superoxide dismuatse mimetic Tempol, 5mM, SD+T, Fig D ). Results were reproduced in a different cell type (rat cardiomyoblast, data not shown). Conclusion: Changes in oxidative stress in MSCs can be monitored using molecular imaging. Reporter Gene-based Molecular Imaging, a strategy that is clinically applicable, provides the opportunity to monitor stem cell survival in the living subject.
Abstract 4879: Overexpression of GTP-Cyclohydrolase I in Vascular Endothelium Prevents Oxidative Stress-Induced eNOS Translocation From Caveolae to Cytosol
Peterson, Timothy E., Katušić, Zvonimir S. , d’Uscio, Livius V.

Circulation | April 23, 2024 | Volume: 120 | Issue: suppl_18 | Pages: No page available

10.1161/circ.120.suppl_18.s1011-c Get It

GTP-Cyclohydrolase I (GTPCH I) is the rate-limiting enzyme for tetrahydrobiopterin biosynthesis, an essential co-factor required for enzymatic activity of endothelial nitric oxide synthase (eNOS). Recent studies have suggested that endothelium-targeted overexpression of GTPCH I has vasoprotective effects. Therefore, we hypothesized that in endothelium GTPCH I localization in caveolae protects eNOS against oxidative stress. Human umbilical vein endothelial cells (HUVECs) were incubated with recombinant adenovirus encoding the human GTPCH I gene (Ad-GTPCH I, 100 MOI) or control recombinant adenoviral vector (Ad-ΔE1) for 12 hours in serum-free media. Cells were then fed with growth medium for 48 hours prior to analysis. Using sucrose gradient ultracentrifugation we detected both protein expression and enzymatic activity of GTPCH I in caveolar microdomains of HUVECs. Treatment of Ad-ΔE1 transduced endothelial cells for 24 hours with LY83583 (1 μ M), a superoxide anion generator, significantly decreased enzymatic activity of GTPCH I in caveolae-enriched membranes (0.49±0.12 pmol neopterin/mg protein; P<0.05 vs. control: 0.92±0.07 pmol neopterin/mg). Furthermore, LY83583 translocated eNOS from caveolae to cytosol in Ad-ΔE1 treated endothelial cells (P<0.05; n=3). This effect was specific because there was no change in caveolin-1 expression and no decrease in cell viability. Treatment of HUVECs with Ad-GTPCH I significantly increased GTPCH I activity in caveolae-enriched membranes (1.37±0.22 pmol neopterin/mg; P<0.05; n=4). Interestingly, LY83583-induced dislocation of eNOS from caveolar membrane fraction was significantly prevented by overexpression of GTPCH I (P<0.05; n=3). Our results suggest that overexpression of GTPCH I increases its enzymatic activity in caveolae. This effect preserves strategically key localization of eNOS in cell membrane during oxidative stress. This research has received full or partial funding support from the American Heart Association, National Center.
2006 Helen B. Taussig Memorial Lecture—Plato, Epistemology, and Cardiology, or, Should Doctors Think Like Lawyers?
Driscoll, David O

Circulation | April 23, 2024 | Volume: 114 | Issue: suppl_18 | Pages: No page available

10.1161/circ.114.suppl_18.ii_e-a Get It

Mistakes occur because doctors make diagnoses and therapeutic decisions on the basis of what they think is correct knowledge but is, in fact, incorrect knowledge. Attainment of knowledge relies on sense experience, and sense experience can be misleading. Medical tests are interfaces between patients and doctors, and sense experiences are distorted by these interfaces. Knowledge can be attained by “reasoning.” Deductive reasoning, utilizing a properly constructed syllogism, is the only way one attains knowledge with 100% certainty. Knowledge attained by all other methods is only correct with a probability <100%. In addition to reasoning, one can gain knowledge on the basis of appeals to authority (eg, expert witness), experience, intuition, revelation, and faith. The level of certainty of knowledge that one can achieve is related to the method used to achieve that knowledge; deductive reasoning is more reliable, for example, than intuition, revelation, or faith. Doctors and lawyers must determine what is true or correct about matters that are uncertain or contingent. Doctors, like lawyers, deal with evidence (medical history and test results). To avoid errors, doctors must treat evidence with the same level of skepticism that lawyers do. Doctors must be aware of what constitutes quality of evidence. If they are not, medical errors will result. In summary, doctors must understand the basic principles of epistemology. Doctors never deal with 100% certain knowledge and hence must rely upon “wisdom,” which is the ability to make the right decision in the absence of certain knowledge.
Abstract 584: Simultaneous Antagonism of the V2 Receptor with Tolvaptan and Activation of the Natriuretic Peptide A-Receptor with B-Type Natriuretic Peptide: A Novel Strategy to Physiologically Enhance Water and Sodium Excretion Without Adversely Affecting
Costello‐Boerrigter, Lisa C. , Boerrigter, Guido, Harty, Gail J., Burnett, John C

Circulation | April 23, 2024 | Volume: 114 | Issue: suppl_18 | Pages: No page available

10.1161/circ.114.suppl_18.ii_94 Get It

Background: Water and sodium (Na) retention are hallmarks of congestive heart failure (CHF). While widely employed, conventional diuretics may adversely affect renal function. Therefore, physiological strategies that enhance water and Na excretion while maintaining renal function are a high priority. Arginine vasopressin (AVP) increases water reabsorption after binding to the V2 receptor in the collecting duct (CD). In contrast, B-type natriuretic peptide (BNP) decreases Na reabsorption via activation of the NPR-A receptor also in the CD and at higher doses also in the proximal tubule. We hypothesized that coadministration of the V2-receptor antagonist tolvaptan (TLV) and BNP would mediate a potent diuresis and natriuresis without adversely affecting renal hemodynamics in experimental CHF. We also assessed plasma and urinary excretion of AVP. Methods: Severe CHF was induced in 2 groups of dogs by tachypacing. On day 11 cardiorenal function was assessed. One group received TLV alone (0.1 mg/kg IV bolus; n=6), whereas the other group received infusion of BNP (50 ng/kg/min) in addition to TLV (n=5). Results: Renal hemodynamics were preserved in both groups. TLV alone increased urine flow from 0.07±0.01 to 0.48±0.09 mL/min, while urinary Na excretion (UNaV) remained unchanged. TLV+BNP-50 increased urine flow from 0.17±0.07 to 2.58±0.47 mL/min and UNaV from 1±1 to 77±23 uEq/min while decreasing proximal fractional Na reabsorption (all p<0.05 vs. TLV alone). TLV alone increased plasma aldosterone and distal fractional Na reabsorption, both of which were prevented with BNP-50. In addition, while plasma AVP did not change with TLV or TLV+BNP, urinary AVP excretion markedly increased with TLV+BNP (from 16±5 to 694±196 pg/min) as compared to TLV alone (from 1±1 to 69±23 pg/min). Conclusions: TLV and BNP coadministration enhances aquaresis and natriuresis through proximal and distal tubular actions without changing renal hemodynamics. Further, TLV with BNP uniquely enhances urinary elimination of AVP warranting further study. We conclude from these findings in experimental CHF that simultaneously antagonizing the V2 receptor by TLV and activating the NPR-A receptor with BNP may be a novel and physiologic diuretic and natriuretic strategy in overt CHF.
Peripherally-derived LGI1-reactive monoclonal antibodies cause epileptic seizures in vivo
Upadhya, Manoj A. , Kirmann, Toni , Wilson, Max A , Simon, Christian M. , Dhangar, Divya , Williams, Robyn , Woodhall, Gavin L. , Hallermann, Stefan , Irani, Sarosh R. , Wright, Sukhvir , Woodhall, Gavin , Irani, Sarosh R , Wright, Sukhvir K , Geis, Christian

Brain | April 23, 2024 | Volume: 147 | Issue: 8 | Pages: 2636-2642

10.1093/brain/awae129 | PMID 38662480 Get It

Abstract One striking clinical hallmark in patients with autoantibodies to leucine-rich glioma inactivated 1 (LGI1) is the very frequent focal seizure semiologies, including faciobrachial dystonic seizures (FBDS), in addition to the amnesia. Polyclonal serum IgGs have successfully modelled the cognitive changes in vivo but not seizures. Hence, it remains unclear whether LGI1-autoantibodies are sufficient to cause seizures. We tested this with the molecularly precise monoclonal antibodies directed against LGI1 [LGI1-monoclonal antibodies (mAbs)], derived from patient circulating B cells. These were directed towards both major domains of LGI1, leucine-rich repeat and epitempin repeat, and infused intracerebroventricularly over 7 days into juvenile male Wistar rats using osmotic pumps. Continuous wireless EEG was recorded from a depth electrode placed in hippocampal CA3 plus behavioural tests for memory and hyperexcitability were performed. Following infusion completion (Day 9), post-mortem brain slices were studied for antibody binding and effects on Kv1.1. The LGI1-mAbs bound most strongly in the hippocampal CA3 region and induced a significant reduction in Kv1.1 cluster number in this subfield. By comparison to control-Ab injected rats video-EEG analysis over 9 days revealed convulsive and non-convulsive seizure activity in rats infused with LGI1-mAbs, with a significant number of ictal events. Memory was not impaired in the novel object recognition test. Peripherally-derived human LGI1-mAbs infused into rodent CSF provide strong evidence of direct in vivo epileptogenesis with molecular correlations. These findings fulfill criteria for LGI1-antibodies in seizure causation.
Non‐alcoholic fatty liver modifies associations of body mass index and waist circumference with cardiometabolic risk: The CARDIA study
Mathew, Mahesh, Pope, Zachary , Schreiner, Pamela J. , Jacobs, David R. , VanWagner, Lisa B. , Pereira, Mark A. , Pope, Zachary C, Pereira, Mark A , Terry, James G , VanWagner, Lisa B , Jacobs, David R , Terry, James G.

Obesity Science & Practice | April 23, 2024 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/osp4.751 | PMID 38655127 Get It

Abstract Background Non‐alcoholic fatty liver disease (NAFLD) is recognized as a prevalent determinant of cardiometabolic diseases. The association between NAFLD and obesity warrants further research on how NAFLD modifies associations between body mass index (BMI) and Waist circumference (WC) with cardiometabolic risk (CMR). Objective This study assessed whether NAFLD modifies associations between BMI and WC with 5‐year changes in CMR in 2366 CARDIA study participants. Methods Non‐contrast CT was used to quantify liver attenuation, with ≤51 Hounsfield Units (HU) used to define NAFLD in the absence of secondary causes of excess liver fat. The dependent variable was the average Z score of fasting glucose, insulin, triglycerides [log], (−) high‐density lipoprotein cholesterol (HDL‐C), and systolic blood pressure(SBP). Multivariable linear regression was used to estimate the associations between BMI and WC with CMR. Effect modification by NAFLD was assessed by an interaction term between NAFLD and BMI or WC. Results The final sample had 539 (23%) NAFLD cases. NAFLD modified the association of BMI and WC with CMR (interaction p < 0.0001 for both). BMI and WC were associated with CMR in participants without NAFLD ( p < 0.001), but not among those with NAFLD. Participants with NAFLD and normal BMI and WC had CMR estimates that were higher than those without NAFLD in the obese categories. Among those without NAFLD the 5 years CMR change estimate was 0.09 (95% CI: 0.062, 0.125) for BMI ≥30 kg/m 2 compared to −0.06 (−0.092, −0.018) for BMI < 25 kg/m 2 , and among those with NAFLD, these estimates were 0.15 (0.108, 0.193) and 0.16 (−0.035, 0.363). Conclusions NAFLD modifies associations of BMI and WC with CMR. Compared with BMI and WC, NAFLD was more strongly associated with CMR. In the presence of NAFLD, BMI and WC were not associated with CMR. These findings have implications for clinical screening guidelines.
Small intestinal bacterial overgrowth in diabetic gastroenteropathy
Varma, Revati , Chakraborty, Subhankar , Burton, Duane D. , Bailey, Kent R. , Bharucha, Adil E.

Neurogastroenterology & Motility | April 23, 2024 | Volume: 36 | Issue: 7 | Pages: No page available

10.1111/nmo.14798 | PMID 38651669 Get It

Abstract Background Although diabetic gastroenteropathy (DGE) is associated with small intestinal bacterial overgrowth (SIBO), most studies have evaluated SIBO with a hydrogen breath test, which may be affected by altered transit in DGE. The risk factors for the consequences of SIBO in DGE are poorly understood. We aimed to evaluate the prevalence of, risk factors for, and gastrointestinal symptoms associated with SIBO in patients with DGE. Methods In 75 patients with DGE and dyspepsia, we tested for SIBO (≥10 5 colony forming units /mL of aerobic and/or anaerobic bacteria in a duodenal aspirate) and assessed gastric emptying (GE) of solids, symptoms during a GE study and during an enteral lipid challenge (300 kcal/2 h), and daily symptoms with a Gastroparesis Cardinal Symptom Index diary for 2 weeks. Symptoms and GE were compared in patients with versus without SIBO. Key Results Of 75 patients, 34 (45%) had SIBO, which was not associated with the use of proton pump inhibitors, daily symptoms, GE, or symptoms during a GE study. During enteral lipid challenge, severe nausea ( p = 0.006), fullness ( p = 0.02) and bloating ( p = 0.009) were each associated with SIBO. Twenty patients (59%) with versus 13 (32%) without SIBO had at least one severe symptom during the lipid challenge ( p = 0.006). Conclusions & Inferences Among patients with DGE 45% had SIBO, which was associated with symptoms during enteral lipid challenge but not with delayed GE, symptoms during a GE study, or daily symptoms. Perhaps bacterial products and even fatty acids are recognized by and activate mast cells that drive the increased lipid sensitivity in SIBO.
The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder
Cameron, Anne P., Chung, Doreen E. , Dielubanza, Elodi , Enemchukwu, Ekene , Ginsberg, David A. , Linder, Brian J. , Rovner, Eric S., Souter, Lesley , Welk, Blayne , Cameron, Anne P. , Linder, Brian J , Helfand, Brian T. , Reynolds, William M. , Suskind, Anne M. , Takacs, Elizabeth B. , Smith, Ariana L.

Journal of Urology | April 23, 2024 | Volume: 212 | Issue: 1 | Pages: 11-20

10.1097/ju.0000000000003985 | PMID 38651651 Get It

Minimum 5-Year Clinical and Return-to-Sport Outcomes After Primary Arthroscopic Scapulothoracic Bursectomy and Partial Scapulectomy for Snapping Scapula Syndrome
Rupp, Marco‐Christopher , Geissbuhler, Annabel R. , Amendola, Richard L., Hanson, Jared A. , Doan, Kent C. , Hazra, Rony-Orijit Dey , Millett, Peter J. , Hanson, Jared A , Millett, Peter J , Rutledge, Joan C.

The American Journal of Sports Medicine | April 23, 2024 | Volume: 52 | Issue: 6 | Pages: 1449-1456

10.1177/03635465241243072 | PMID 38651596 Get It

Background: Snapping scapula syndrome (SSS) is a rare condition that is oftentimes debilitating. For patients whose symptoms are resistant to nonoperative treatment, arthroscopic surgery may offer relief. Because of the rarity of SSS, reports of clinical outcomes after arthroscopic SSS surgery are primarily limited to small case series and short-term follow-up studies. Purpose: To report minimum 5-year clinical and sport-specific outcomes after arthroscopic bursectomy and partial scapulectomy for SSS and to identify demographic and clinical factors at baseline associated with clinical outcomes at minimum 5-year follow-up. Study Design: Case series; Level of evidence, 4. Methods: Patients who underwent arthroscopic bursectomy and partial scapulectomy for SSS between October 2005 and February 2016 with a minimum of 5 years of postoperative follow-up were enrolled in this single-center study. Clinical outcome scores, including the 12-Item Short Form Health Survey (SF-12), American Shoulder and Elbow Surgeons (ASES) Shoulder Score, shortened version of the Disabilities of the Arm, Shoulder and Hand (QuickDASH) score, Single Assessment Numeric Evaluation (SANE), and visual analog scale (VAS) score for pain, were collected at a minimum 5-year follow-up. Additionally, it was determined which patients reached the minimal clinically important difference. Bivariate analysis was used to determine whether baseline demographic and clinical factors had any association with the outcome scores. Results: Of 81 patients eligible for inclusion in the study, follow-up was obtained for 66 patients (age 33.6 ± 13.3 years; 31 female). At a mean follow-up of 8.9 ± 2.5 years (range, 5.0-15.4 years), all of the outcome scores significantly improved compared with baseline. These included the ASES (from 56.7 ± 14.5 at baseline to 87.2 ± 13.9 at follow-up; P < .001), QuickDASH (from 38.7 ± 17.6 to 13.1 ± 14.6; P < .001), SANE (from 52.4 ± 21.2 to 82.7 ± 19.9; P < .001), SF-12 Physical Component Summary (from 39.7 ± 8.3 to 50.3 ± 8.2; P < .001), SF-12 Mental Component Summary (from 48.2 ± 11.7 to 52.0 ± 9.0; P = 0.014) and VAS pain (from 5.2 ± 2.1 to 1.4 ± 2.0; P < .001). The minimal clinically important difference in the ASES score was reached by 77.6% of the patients. Median postoperative satisfaction was 8 out of 10. It was found that 90.5% of the patients returned to sport, with 73.8% of the patients able to return to their preinjury level. At the time of final follow-up, 8 (12.1%) patients had undergone revision surgery for recurrent SSS symptoms. Older age at surgery ( P = .044), lower preoperative SF-12 Mental Component Summary score ( P = .008), lower preoperative ASES score ( P = .019), and increased preoperative VAS pain score ( P = .016) were significantly associated with not achieving a Patient Acceptable Symptom State on the ASES score. Conclusion: Patients undergoing arthroscopic bursectomy and partial scapulectomy for SSS experienced clinically significant improvements in functional scores, pain, and quality of life, which were sustained at a minimum of 5 years and a mean follow-up of 8.9 years postoperatively. Higher patient age, inferior mental health status, increased shoulder pain, and lower ASES scores at baseline were significantly associated with worse postoperative outcomes.